Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? [Yahoo! Finance]
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: Yahoo! Finance
Friedreich's Ataxia, showing benefits at both 25 mg and 50 mg doses through daily subcutaneous self-injection. This development marks a significant step for Larimar in providing new therapeutic options for a rare, progressive neurodegenerative condition with high unmet medical need. We'll explore how the positive clinical data on nomlabofusp could impact the company's long-term role in rare disease treatment. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality What Is Larimar Therapeutics' Investment Narrative? To get behind Larimar Therapeutics, you'd need to believe in its ability to deliver a first-of-its-kind therapy for Friedreich's Ataxia, a rare and debilitating disorder with few available treatment options. The newly announced positive results from the long-term study of nomlabofusp could be a meaningful catalyst, potentially reducing regulatory risks around the Biologics License Application and improving t
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMRBusiness Wire
- LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRPR Newswire
LRMR
Earnings
- 11/5/25 - Miss
LRMR
Sec Filings
- 11/10/25 - Form 8-K
- 11/6/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- LRMR's page on the SEC website